For personal use only

Similar documents
For personal use only

FY13 results presentation 29 August 2013 Geoffrey Babidge Managing Director & CEO

a2 Milk, a2 Platinum and The a2 Milk Company are trade marks of The a2 Milk Company Limited

20 August Geoffrey Babidge. Managing Director & CEO

For personal use only

Investor Presentation

FY16 Full Year Results Geoffrey Babidge August a2 Milk, a2 Platinum and The a2 Milk Company are trademarks of The a2 Milk Company Limited

CLSA Investors Forum. Hong Kong September a2 Milk, a2 Platinum and The a2 Milk Company are trademarks of The a2 Milk Company Limited

UBS Australasia Conference

FY17 Full Year Results

For personal use only

ANNUAL MEETING 2016 GEOFFREY BABIDGE MANAGING DIRECTOR & CEO 22 NOVEMBER

For personal use only

For personal use only. Interim report for the six months ended 31 December 2017

For personal use only

It s subsidiary CS&Co distributes international cosmetics, fragrances, skincare and haircare brands in New Zealand. Consumer Product Brands

Barry Irvin Executive Chairman Aidan Coleman CEO. Annual General Meeting 27 October 2015

FY17 highlights

7 March Senior Executive, Financial Market Infrastructure. Level 5, 100 Market Street SYDNEY NSW 2000 SYDNEY NSW 2000

8.4 % +56 % 84 % $155m. FY17 highlights. $550m - $141m c - $91m - ANZ EBITDA +83 % Group Revenue. and EBITDA +159%

Cover-More Group. UBS Australasia Conference. November 2015

FONTERRA INTERIM RESULTS 2014

Tegel Group Holdings Limited

For personal use only

Preliminary Unaudited Announcement for the year ended 31 March 2018

Half year result. 26 August 2016

Full Year results and outlook

Interim Results 2019 March 2019

WELCOME 55 th ANNUAL GENERAL MEETING BLACKMORES LTD 26 OCTOBER 2017

Crowd Mobile Ltd. Track Deal Drives Valuation Upgrade BUY. Valuation $0.63

ASX ANNOUNCEMENT. Half Year 2019 Results Highlights Presentation

Half-Year 2016 Results Presentation

ANNUAL Report. for the year Ended 30 June 2010

NZX IPO MASTERCLASS The Wynyard Listing Story. 5 September 2014

Company Directory 1. Chairman s Report 2. Managing Director s Report 3. Directors Responsibility Statement 6. Audit Report 7

FY 2018 Full Year Results Investor Presentation. 27 th August 2018

FUA. For personal use only INVESTOR PRESENTATION. $5b $4b. $3b 7 months $2b 11 months $1b 27 months $100m June 12

9 June Senior Executive, Financial Market Infrastructure. Level 5, 100 Market Street SYDNEY NSW 2000 SYDNEY NSW 2000

Update following MG Capital Structure Workshops

1H FY16 RESULTS PRESENTATION

FONTERRA ANNUAL RESULTS FONTERRA CO-OPERATIVE GROUP LIMITED Fonterra Co-operative Group Ltd.

Sigma Pharmaceuticals Limited

METHVEN LIMITED. Results for announcement to the market

Page Key Financial Highlights Key Drivers of Improved Profitability Strategy Global Sales Revenue Franchisee Sales Revenue 10 Review of the Income

John Wilson - Chairman. Fonterra Co-operative Group Ltd. #

Business Update Q4 and FY 2015 March 15, 2016

Media Release 11 February 2016

Company Results Half Year ended 4 January 2009

For personal use only

NEWS RELEASE FOR IMMEDIATE RELEASE

Investor & Analyst Presentation Ful YearResults 30 June2016 For personal use only 25th August 2016 Rebekah O Flaherty - CEO I Jonathan Kenny - CFO

Full Year Results to 30 June 2016 Jeff Greenslade Simon Owen Chris Flood. Annual Meeting 1 November 2013 Page 1

For personal use only

Interim Results For 6 months ended 31 Dec February 2018

For personal use only. Investor Update 13 August 2018

For personal use only

Kathmandu Holdings Limited

The a2 Milk company (A2M)

Trustpower Annual General Meeting 25 July 2017

Inghams Group Limited. FY2018 Results Presentation

Methven Group Interim Results Outperform Guidance

Kathmandu Holdings Limited

Fevertree Drinks plc. Preliminary Results. Year ended 31 December 2014

LIFE STARTS HERE. FY18 Full Year Results Presentation. 27 August 2018

NEXTDC Ltd. Background

For personal use only

Telecom Corporation of New Zealand

A new inflection point. 10 February 2017

Agenda. Welcome. Chairman s address. CEO review. General business. Refreshments

RESTAURANT BRANDS 2016 ANNUAL RESULT (52 weeks) $m

rhipe Limited (ASX code RHP) FY16 Full Year Results Presentation & FY 2017 Outlook

INDUSTRY SNAPSHOT. Milk Powder Manufacturing

For personal use only. FY2017 H1 Results February 2017

NUPLEX INDUSTRIES LIMITED RESULTS PRESENTATION FOR THE YEAR ENDED 30 JUNE 2012 PRESENTATION AGENDA

Half-Year 2017 Results. ASX Limited. 17 February 2017

Full-Year 2016 Results Presentation

(RBD) INVESTOR PRESENTATION

SKYCITY Entertainment Group Limited. FY16 Full-Year Result Presentation 10 August SKYCITY Entertainment Group Limited

Monash IVF Group. FY16 Results Presentation 26 August 2016

FY2018 Full Year Roadshow Presentation. Barry Irvin Executive Chairman Paul van Heerwaarden CEO Colin Griffin CFO

THINKSMART 2009 Half Year Results Presentation: 21 st August 2009

Half Year Results to 31 December February 2018

PRELIMINARY RESULTS Investor Presentation Year ended 30 June 2017

For personal use only

Attached is the ASX / Media Release in relation to the results for the year ended 30 June 2018.

Telecom NZ. Investor Presentation. Theresa Gattung, CEO Marko Bogoievski, CFO. March 2005

Serko Limited FY19 Interim Results for the period ended 30 September 2018

1H 19 Investor Presentation February 2019

Investor Briefing. Sandler O Neill Global Exchange and Brokerage Conference. Elmer Funke Kupper, CEO. 4 June 2014

Business outlook 13 November 2018

ASX ANNOUNCEMENT CELLMID LIMITED NOTES TO THE APPENDIX 4C. Highlights for the quarter ending 31 December 2018

2015 ANNUAL RESULTS SEPTEMBER 2015 JOHN WILSON, CHAIRMAN THEO SPIERINGS, CEO LUKAS PARAVICINI, CFO

For personal use only

For personal use only. Investor Presentation November 2012

First Quarter 2015 Earnings. May 11, 2015

For personal use only

RM plc ("RM" or the "Company") PROPOSED ACQUISITION OF THE EDUCATION & CARE BUSINESS OF CONNECT GROUP PLC

For personal use only


Named by Forbes Magazine One of America's Best Managed Companies in 2005 and One of America s Best Big Companies in 2006

Transcription:

ASX Code: A2M NZX Code: ATM 03 June 2015 NZX/ASX Market Release Investor presentation: UBS Emerging Companies Conference Please find attached a presentation to be shared by The a2 Milk Company Limited at the UBS Emerging Companies Conference Series on 3 rd June 2015. For further information contact: Geoffrey Babidge Managing Director The a2 Milk Company Limited +61 2 9697 7000 The a2 Milk Company Limited a2mc is a differentiated, premium company which is building a global business based on unique intellectual property relating to a2 Milk branded dairy and infant formula products. a2mc has operations in Australia, New Zealand, the UK, China and the USA. a2mc is dual listed on the NZX and ASX and trades under the codes ATM and A2M respectively. The a2 Milk Company Limited ARBN 158 331 965, incorporated in New Zealand

UBS Emerging Companies Series June 2015

The a2 Milk Company (a2mc) at a glance a2mc is in the business of producing, marketing and selling branded dairy and infant formula products in targeted global markets a2mc branded products contain only A2 betacasein protein rather than both A1 protein and A2 protein which are found in regular cows milk products a2mc sees itself as different from many other dairy businesses: 1 2 3 Focussed on building a high margin and differentiated business supported by an integrated IP portfolio Seek to achieve upper quartile ROC through investment in brand building and outsourced manufacturing Distinctive products that have broad appeal across a number of developed and emerging markets Product portfolio Global presence Key metrics Liquid Milk Fresh milk Long life milk UK Entered: 2012 FY14 revenue 1 : NZ$1.1m China Entered: 2013 FY14 revenue: NZ$2.7m Share Price 2 Market Capitalisation 2 NZ$0.49 NZ$336.6m Infant formula Other dairy products FY14 Sales NZ$110.6m Cream Yoghurt FY14 EBITDA NZ$3.6m USA Entered: April 2015 Australia, NZ Entered: 2003 FY14 revenue: NZ$106.9m Median Analyst Target Share Price 3 NZ$0.76 1 FY14 Revenue represents revenue for six month period from 1 Jan 2014 to 30 Jun 2014, following the acquisition of the remaining 50% shareholding in the UK business from Müller Wiseman Dairy 2 Price as at 29 May 2015 3 Broker price targets, Thomson Reuters a2 Milk, a2 Platinum and The a2 Milk Company are trademarks of The a2 Milk Company Limited 2

Brief company history 1 2000 The a2 Milk Company is founded by scientist Dr. Corran McLachlan and his business partner Howard Paterson - armed with intellectual property and growing belief of the effect different milk proteins have on human health 2004 Listed on NZX Alternative Market 2007 JV with Freedom Foods formed for the production and marketing of the a2 Milk brand in Australia 2008 Consumer and healthcare professional advocacy in Australia accelerates brand growth 2012 Commissioned new milk processing facility in Sydney, Australia Launch a2 Milk into the UK fresh milk market through JV with Robert Wiseman Dairies Listed on NZX Main Board 2013 a2platimun infant formula is launched in China, Australia and New Zealand 2014 a2mc fully acquires UK JV. New management team and consumer proposition put in place a2 Milk Australia extends into thickened cream and continues to drive market share growth in the fresh milk supermarket category First human digestion trial published in European Journal of Clinical Nutrition reporting a digestive difference between A1 and A2 protein supporting previous studies 2015 Listed on the ASX a2mc to launch a2 Milk into the California region from mid April via a wholly owned subsidiary 1 Years shown are based on calendar years 3

Investment highlights a2mc is not a conventional dairy company 01 04 Premium brand and product range supported by an integrated intellectual property portfolio Flexible and scalable supply chain allows optimisation of return on capital 03 Differentiated product portfolio has broad appeal across both developed and emerging international markets 05 02 Profitable Australian business has grown rapidly providing a platform for additional growth Senior management team with relevant industry and market experience and focus on creating value for shareholders 4

What is a2 Milk branded milk? A naturally occurring cows milk and not a product of genetic engineering or technological processes Regular cows milk contains 2 main types of beta-casein protein: A2 protein and A1 protein. a2mc branded milk contains only the A2 protein. It is comparable to regular cows milk in other respects The variance in structure between A1 and A2 proteins results in these proteins being broken down differently during digestion Where does a2mc branded milk come from? A2/A2 A1/A1 A2/A2 ~70% Typical cow herds produce milk containing a mix of A1 and A2 proteins A2/A2 Originally all cows produced milk containing only A2 protein Genetic variation has resulted in mixed herds A1/A2 ~30% A2/A2 a2mc branded milk is sourced from herds producing milk containing only A2 protein 5

The a2 Milk brand is focussed on digestive benefits Positive consumer experiences and developing body of research The a2mc brand proposition has evoked a strong response from consumers, in terms of both the health and digestive benefits, in addition to the appeal of taste and freshness Consumers link a2mc branded milk with improved digestive comfort and the reduction of milk sensitivity symptoms A growing body of scientific research has demonstrated a structural difference between the A1 and A2 proteins and the way the digestive system breaks them down During digestion, a fragment produced from A1 but not A2 protein has the potential to interact with a range of cells and tissues, including those involved in the digestive and immune functions a2mc is bringing consumers back to the enjoyment of dairy Strong consumer testimonials advocating how the product works for them I have been pleasantly surprised. My kids are not complaining of tummy aches any more. They are actually asking for glasses of milk, whereas before they would only ask for water or juice. My son loves the taste. I love the taste. Adrianna, Australia Milk taste is very pure, not over sweet, natural, fresh and lets me feel relieved. Hannah, China Since switching to a2 Milk, I m able to enjoy dairy again. This has improved my overall wellbeing, and helps me to train everyday. Robert, Australia a2 Milk has truly changed our lives. My son, Noah, has terrible reflux and was constantly ill. It wasn t until I discovered a2 Milk that I realised the cause was the A1 protein. Almost immediately his reflux stopped and he was happy again. Sara, United Kingdom 6

a2mc proposition aligns with growing consumer demand for health and well-being General health and well-being growth trends 1 Global health and wellness dairy market (US$ bn) Global consumers are becoming increasingly focussed on their health and well-being leading to significant growth in health and wellness dairy products markets Growing level of demand for products tailored to food sensitivities 1 Sales of free-from foods in the UK ( million) Sensitivities are an increasing consumer concern and hence strongly influence the purchasing behavior of young families (key a2mc consumer target) 1 a2mc Information Memorandum, February 2015 7

Targeted and differentiated consumer proposition Distinctive and premium product portfolio Based around the benefits of A1 protein free products LIQUID MILK INFANT FORMULA OTHER DAIRY PRODUCTS FRESH MILK Australia, UK, China, USA LONG LIFE MILK Australia, China INFANT FORMULA Australia, New Zealand, China CREAM Australia YOGHURT Australia a2mc consumer a2mc primarily targets consumers who don t get on with regular milk - in Australia, this is approximately 19% of milk drinkers 1 In doing so, a2mc finds it also attracts health conscience and progressive consumers despite not having issues consuming milk Differentiated brand communication Product portfolio is underpinned by differentiated communication strategy with programs targeting both consumers and health care professionals a2mc employs category-distinctive advertising and social media. These focus on highlighting potential benefits to consumers Health care professional programs are a key way of introducing a2mc branded products to consumers 1 EY Sweeney Brand Health Study, August 2014. Sample size 1,379 8

Integrated portfolio of intellectual property and proprietary know-how Developed and continuing to enhance the scope of its integrated intellectual property portfolio Portfolio combined with wide geographical coverage means potential competitors have restricted ability to produce and sell competing A1 protein free products, with limitations in major markets around production, communication, branding, positioning and promotion Brands and trade marks Trade mark registrations / applications across ~57 territories 1 The a2 Milk Company TM True A2 TM Feel the Difference TM Research and Development Focus on providing new IP Partners with 3 rd party research institutions to enhance suite Owns confidential information, data and trade secrets associated with production, testing and marketing of products 9 families of patents Rights to 9 families of patents and patent applications Portfolio strength derived from interlocking relationships, complexity and geographical spread Covers a spectrum of activities including testing, herd formation, beneficial uses and physical properties associated with A1 protein free milk products The a2 System Proprietary processes and know-how codified in a confidential suite of proprietary documents Covers all aspects from milk supply to consumer 1 As at 27 January 2015 9

Scalable and flexible supply chain 1. Milk supply Milk sourced from segregated dairy herds 2. Processing 3. Distribution Milk processed at a2mc Contractors distribute facilities or contracted 3 rd products to outlets/ party facilities wholesalers The a2 Milk Company value creation 4. Retail/consumer Products sold through a variety of channels Farm selection procedures Assist farmers with breeding and herd maintenance Use separate storage vats and milking procedures Milk validated as A1 protein free Milk transported in segregated tankers Milk stored in isolated vats Contracts with 3 rd party providers, distributors and wholesalers Maintains quality control for storage and delivery Contracts with supermarket chains and retail outlets Education initiatives Investment in brand and trade mark portfolio a2mc advanced testing and record keeping Plentiful supply of cows producing A1 protein free milk Premium farm gate milk price Established and efficient proprietary practices and testing procedures Key features making the supply chain scalable Available third party processing capacity Control of brand and consumer marketing in core markets 10

Focussed and consistent strategic growth map STRATEGIC INTENT Continue to build a substantial premium dairy business in Australia and NZ STRATEGIC PRIORITIES 1. Australian growth in liquid milk and other dairy products 2. Investigate NZ liquid milk opportunity in advance of Fresha Valley s license expiring in 2017 Capture sustainable shares for premium a2mc branded products in targeted global dairy markets 1. Re-set of UK business 2. USA milk market entry, initially in the West Coast region, April 2015 3. Progress China liquid milk opportunity utilising Australian exports 4. Explore other priority Asian markets Establish and build a global infant formula business 1. Strengthen the a2 Platinum brand presence in China amongst targeted consumer group 2. Capitalise on the Australian business position and build upon current launch momentum of a2 Platinum infant formula 3. Seeking additional market opportunities 11

Australia and New Zealand Current position Significant branded milk business with a reliable supply chain, strong sales growth and premium pricing Segment revenue grew by 39% in 1H15 vs PCP ~9.3% market share 1 Modern purpose-built processing facility in Sydney and developed distribution network Growth strategy Enhance brand strength Build core ANZ liquid milk businesses Grow a2 Platinum infant formula business Launch new dairy products Build scale and efficiency Infant formula sales shown strong growth. a2 Platinum now ranged in Coles, Woolworths, Independents and Pharmacy 1 By value in the Australian grocery channel of total fresh milk (Australian Grocery Weighted Scan, Dec-2014) 12

United Kingdom Current position Entered UK market in 2011 through a JV with Robert Wiseman Dairies Revised arrangements and business model in calendar 2014 End-to-end supply chain and a growing distribution network with products being sold in Tesco, Waitrose, Morrisons, Ocado, J Sainsbury and Wholefoods and wholesaler, Marigold Growth strategy Build targeted premium brand Reposition existing fresh milk business Build distribution Expand product portfolio Plan to invest ~ 3.5m to fund growth in the UK market during FY15 13

USA entry plan underway Entry concentrated initially in West Coast region from April 2015, prior to extending distribution into further state markets Progressive launch commenced from Southern California in April with distribution planned to build to ~70% of grocery weighted distribution by end of July 2015 in this region Other significant progress in market Appointment of high calibre local CEO, Jeff O Neill, former PepsiCo / Quaker Foods senior executive Core USA based team recruited to manage sales, marketing, logistics, administration Administration office based in Boulder Colorado Product format in ½ gallon carton, consistent with specialty milk category Quality partner contracted to manage milk supply and processing Initial investment of ~US$20m over 3 years to fund entry and working capital requirements 14

China Current position Infant formula supply chain Launched a2 Platinum infant formula in Nov-13 with the intention of establishing a position in China before expanding into other Asian markets Infant formula processed and packaged by Synlait who has an integrated facility that allows full manufacturing and packaging control Milk sourced from suppliers in NZ Infant formula manufactured by Synlait on behalf of a2mc in NZ Imported into China by China State Farm Distributed by a2mc via 3 rd party arrangements Focus on sale initially within mother and baby stores, online and high-end supermarkets a2mc oversees the distribution, marketing and communication activities of a2 Platinum Now selling fresh milk and exploring opportunities for the sale of long life milk Growth strategy Build a recognised premium brand in China Build core infant formula and liquid milk business Enhance supply chain efficiency Build relationships with distributors 15

China market opportunity a2mc s entry into the Chinese infant formula market represents a foothold in one of the fastest growing regions globally Management expects that consumer and economic trends will continue to drive growth in the premium and ultra-premium infant formula segments Growth in the liquid milk market provides further opportunities for Australian exports into the Chinese market Consumer product trialling favourably supports the a2mc proposition 1 Chinese infant formula market size (US$ billion) 2 Chinese liquid milk market size (US$ billion) 3 8.6 2013-2018 CAGR: 11% 10.4 11.5 12.8 14.5 16.2 17.8 2013-2018 CAGR: 8% 10.3 11.2 12.0 13.0 14.1 15.3 16.6 2012 2013 2014 2015 (fore) 2016 (fore) 2017 (fore) 2018 (fore) 2012 2013 2014 2015 (fore) 2016 (fore) 2017 (fore) 2018 (fore) 1 AcNielsen milk intolerance product trial, March 2014, Shanghai 2 Source: Canadean and ERC valuations based on trade sources 2014 3 Source: Canadean China Dairy Report May 2015 (excludes flavoured milk) 16

Summary historical financial performance Strong sales growth driven primarily by the Australian and New Zealand segment a2mc business model is focussed on revenue growth in key markets through re-investment of Australia and New Zealand earnings Generated positive EBITDA since FY11 Reduction from FY13 FY14 a result of increased marketing and corporate costs to support international growth initiatives and the inclusion of costs associated with the UK business (previously reported as a share of loss of associates) Sales FY11 1H15 (NZ$m) EBITDA before non-recurring items FY11 1H15 (NZ$m) CAGR: 37.9% 94.3 110.6 10.6 42.2 62.5 74.7 2.8 4.7 3.6 3.3 FY11 FY12 FY13 FY14 1H15 FY11 FY12 FY13 FY14 1H15 17

1H15 Financial highlights NZ$ million 1H14 1H15 % change Revenue 54.2 74.8 +38% Gross margin 19.9 26.1 +31% EBITDA before nonrecurring items 2.6 3.3 1 +27% EBITDA 2.6 2.5-3% EBIT 1.7 1.6-6% NPAT 0.6 0.1-81% Other expenses 8.0 2 10.7 +34% Cash on hand 13.2 9.9-25% Notes: 1. Non-recurring items represent ASX listing costs of $0.8 million in 1H15 2. 1H14 includes $4.1m freight costs, $3.9 million other operating expenses Revenue growth of 38% on PCP Gross margin reflects higher milk costs in Australia and modest UK margin to date EBITDA before non-recurring items growth of 27% on PCP 1H15 EBITDA and EBIT includes costs of establishing position in the UK of NZ$4.2 million For 1H14 the UK business was reported below the EBIT line as share of JV earnings Foreign exchange movements between the NZD/AUD reduced revenue by ~$2.1 million and EBITDA by ~$300k on PCP 1H15 Other expenses includes $4.7 million freight costs, $0.8 million ASX listing costs, and other operating expenses of $5.2 million. Other operating expenses increased on PCP given costs associated with business growth and consolidation of UK business from 1 January 2014 18

1H15 Financial highlights (cont'd.) 1H15 Segment EBITDA (NZ$ million) Australia and New Zealand $14.0 million ($9.1) million $4.9 million ANZ Operating EBITDA Net intercompany charges* ANZ Segment EBITDA China ($2.2) million +$1.6 million ($0.6) million China Operating EBITDA Net intercompany charges China Segment EBITDA ($4.2) million UK and USA +$2.3 million ($1.9) million UK & USA Operating EBITDA Net intercompany charges UK & USA Segment EBITDA Corporate and Other** ($5.0) million +$5.2 million $0.2 million Corporate & Other EBITDA Net intercompany charges Corporate & Other Segment EBITDA * Net inter-company charges largely include royalties, licence fees and management fees payable to the Parent, and marketing and herd testing costs payable by the Parent ** Inclusive of non-recurring items ($0.8) million 19

Conservative capital position Current business plan has been financed from a combination of equity and operating cash flows Conservative approach to debt given growth profile and orientation Balance sheet net cash position of $9.9m at 31 December 2014 Current strategy assumes growth funded in the first instance from cash flows from existing businesses Whilst there is no present intention to raise capital we will continue to evaluate growth opportunities and the funding implications of these as they arise 20

ASX Listing 31 March 2015 a2mc was admitted to the Official List of the Australian Securities Exchange (ASX) on 31 st March 2015 No capital was raised during the listing, however the listing provides for broader investor participation and improved access to capital markets over time We have seen strong Australian investor participation, with the number of total shareholders increasing 35% since August 2014 1 ASX ticker code A2M Number of Shareholders (NZX/ASX) 2 Investor Domicile 3 4,821 3,566 22.5% 76.5% Aug-14 May-15 NZX ASX New Zealand Australia Other 1 FY14 Annual Report 2 Link Market Services, 28 May 2015 3 Weighting based on number of shares; Link Market Services, 28 May 2015 21

Why is a2mc an attractive investment opportunity? A proven, sustainable, profitable business model in ANZ delivering upper quartile returns on capital relative to the industry Business centred on continuing to build a differentiated premium international brand Continued significant growth opportunities in ANZ International growth targeted in both mature western markets and emerging Asian markets Broad and consistent consumer acceptance of the benefits of A2 protein 22

Disclaimer This presentation dated 03 June 2015 is provided for information purposes only. The information contained in this presentation is not intended to be relied upon as advice to investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Investors should assess their own individual financial circumstances and consider talking to a financial adviser or consultant before making any investment decision. Certain statements in this presentation constitute forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. While all reasonable care has been taken in relation to the preparation of this presentation, none of the Company, its subsidiaries, or their respective directors, officers, employees, contractors or agents accepts responsibility for any loss or damage resulting from the use of or reliance on the presentation by any person. Past performance is not indicative of future performance and no guarantee of future returns is implied or given. Some of the information in this presentation is based on unaudited financial data which may be subject to change. All values are expressed in New Zealand currency unless otherwise stated. All intellectual property, proprietary and other rights and interests in this presentation are owned by the Company. 23